Detection of parathyroid hormone-like hormone in cancer cell cultures by gold nanoparticle-based lateral flow immunoassays.
Parathyroid hormone-like hormone (PTHLH) exerts relevant roles in progression and dissemination of several tumors. However, factors influencing its production and secretion have not been fully characterized. The main limitation is the lack of specific, sensitive and widely available techniques to detect and quantify PTHLH. We have developed a lateral flow immunoassay using gold nanoparticles label for the fast and easy detection of PTHLH in lysates and culture media of three human cell lines (HaCaT, LA-N-1, SK-N-AS). Levels in culture media and lysates ranged from 11 to 20 ng/mL and 0.66 to 0.87 μg/mL respectively. Results for HaCaT are in agreement to the previously reported, whereas LA-N-1 and SK-N-AS have been evaluated for the first time. The system also exhibits good performance in human serum samples. This methodology represents a helpful tool for future in vitro and in vivo studies of mechanisms involved in PTHLH production as well as for diagnostics. From the Clinical Editor: Parathyroid Hormone-like Hormone (PTHLH) is known to be secreted by some tumors. However, the detection of this peptide remains difficult. The authors here described their technique of using gold nanoparticles as label for the detection of PTHLH by Lateral-flow immunoassays (LFIAs). The positive results may also point a way to using the same technique for the rapid determination of other relevant cancer proteins.
Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193 Barcelona, Spain; Hospital Sant Joan de Déu and Fundació Sant Joan de Déu, 08950 Barcelona, Spain.
Alejandro
A
Chamorro-Garcia
Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193 Barcelona, Spain.
Alfredo
A
de la Escosura-Muñiz
Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193 Barcelona, Spain.
Marisol
M
Espinosa-Castañeda
Hospital Sant Joan de Déu and Fundació Sant Joan de Déu, 08950 Barcelona, Spain.
Carlos J
CJ
Rodriguez-Hernandez
Hospital Sant Joan de Déu and Fundació Sant Joan de Déu, 08950 Barcelona, Spain.
Carmen
C
de Torres
Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193 Barcelona, Spain; ICREA-Institucio Catalana de Recerca i Estudis Avançats, 08010 Barcelona, Spain. Electronic address: arben.merkoci@icn.cat.
Arben
A
Merkoçi
D014408:Biomarkers, Tumor / Q000276:immunology; D045744:Cell Line, Tumor; D004867:Equipment Design; D019544:Equipment Failure Analysis; D006046:Gold / Q000737:chemistry; D006801:Humans; D007118:Immunoassay / Q000295:instrumentation*; D053768:Metal Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D046210:Microfluidic Analytical Techniques / Q000295:instrumentation*; D009374:Neoplasms, Experimental / Q000175:diagnosis* / Q000276:immunology*; D010281:Parathyroid Hormone / Q000032:analysis* / Q000276:immunology; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D010281:Parathyroid Hormone; D006046:Gold
HaCaT; LA-N-1; Lateral flow immunoassay (LFIA); Parathyroid hormone-like hormone (PTHLH); SK-N-AS